NINDS Neuroscience Funding Announcements

Funding Resources
Funding Overview
Funding Strategy

Funding Opportunities

Grant Mechanisms
Training & Career
Development
Contracts Management
Review Committees
Funding News
Program Areas

Research
Anticonvulsant Screening
   Program
Clinical Research
Counterterrorism
Epilepsy Research Web
Neural Interfaces Program
NIH Roadmap Research
Parkinson's Web
Resources for Scientists
Stem Cell Research
Translational Research
Traumatic Brain Injury
   (TBI) Research
Technology Transfer
   Office

NINDS is part of the
National Institutes of
Health

Download Adobe Reader

Print-friendly version

Email this page

Application processes at NIH are changing. Applicant organizations are encouraged to start preparing for this transtion by registering with Grants.gov and NIH eRA Commons now.

Collaborative Research to Explore New Uses for Existing Radioligands (R21/R33)
Release Date: August 8, 2007
Announcement Number: RFA-DA-08-001
Application Receipt Date:
January 28, 2008
Letter of Intent Date: December 28, 2007

Funding Contact: Debra Babcock, MD., Ph.D.
Program Area: Systems and Cognitive Neuroscience

Brief Description:
The National Institute on Drug Abuse (NIDA), the National Institute on Aging, the National Institute of Neurological Disorders and Stroke (NINDS), and the National Institute of Mental Health (NIMH), through the issuance of this Request for Applications (RFA), seeks to encourage broader uses of established PET/SPECT radioligands by reducing barriers to their wider distribution, and expanding their utility to the study of diseases or organs for which the radioligand has not previously been studied. Applications for this RFA should demonstrate a high degree of innovation and novelty with regard to the new uses for existing radioligands. Although there is no requirement for preliminary data, a clear scientific rationale is essential. Applications for this RFA are expected to propose multi-institutional collaborations between investigators who have the capacity for routine production of a given radioligand for human use, and investigators who lack access to the radioligand but wish to demonstrate the feasibility of an innovative use for the radioligand in a novel patient population. The primary focus of the proposal must be on human studies; animal studies are allowable only if required to obtain regulatory approval for the ligands.

Choose an option to view additional funding announcements